LUMBAR SPINE DENSITOMETRY BI&TISN
_~~~~~~~~~~~~MEDICAL JOURNAL which in due course will enable us to define the distribution in statistical -terms. In the meantime an R.V.D. ratio of less than unity indicates a vertebral density less than our standard. We are not yet prepared to define the reduction in bone density which justifies the use of the term " osteoporosis," but consider it axiomatic that vertebral bodies which are no denser than their disks are severely porotic. On this basis the data confirm our previous suggestion (Barnett and Nordin, 1960, 1961 ) that our original scoring procedure tends to underdiagnose osteoporosis-that is, it produces false negatives but no false positives. It would in fact appear from Fig. 7 that vertebral biconcavity develops at that stage in osteoporosis when the vertebral bodies have about the same radiographic density as the disks. It may seerm surprising that the vertebral bodies can even become less dense than the disks, but we attribute this to the replacement of bony trabeculae by marrow fat.
Our results appear to resolve the problem of the difference between spinal and peripheral osteoporosis. We had previously suggested (Nordin, 1961 ; Barnett and Nordin, 1961 ) that peripheral osteoporosis might be a late stage in a disease process initiated in trabecular bone, particularly that of the spine, and had pointed out that the occurrence of pure peripheral osteoporosis might be an artifact of our original technique in that it failed to detect early spinal osteoporosis. This now appears to be the case. Examination of Fig. 6 shows that all our cases of peripheral osteoporosis with one exception have low R.V.D. ratios, and we are therefore satisfied that although spinal (that is, trabecular) osteoporosis may occur without peripheral (that is, cortical) osteoporosis, the reverse does not occur. In generalized osteoporosis the first loss of bone is trabecular and only later does cortical loss occur. This accords.with the experimental evidence of the effect of negative calcium balance in animals (Nordin, 1960) , and is therefore compatible with the concept that clinical osteoporosis could be due to prolonged negative calcium balance. Summary A method is described for assessing the density of the lumbar vertebrae by comparison with the intervertebral disks. This procedure is designed to eliminate the effect of soft-tissue variation.
A lateral tomogram is obtained through the centre of the lumbar spine and of a dissected specimen of lumbar spine mounted in formol-saline and placed next to the subject.
The film images of the spine and standard are fed through a Laurence-Locarte recording densitometer and the difference between the average density of the disks and the average density of the bodies is determined. This difference in the spine is divided by the same difference in the standard, and the ratio is called the relative vertebral density.
The results obtained are compared with the x-ray scores of Barnett and Nordin. This Recent reports of the satisfactory response of irondeficient patients to intramuscular administration of an iron-sorbitol-citric-acid complex (iron-sorbitol) (Andersson, 1961; Swedberg, 1962) suggested an investigation in man of the injection-site clearance, organ distribution, and utilization for haemoglobin synthesis of this complex labelled with 59Fe. The pattern of the investigation reported here is similar to the investigation of 5"Felabelled iron dextran previously carried out in this department (Grimes and Hutt, 1957) .
Materials and Subjects 59Fe-labelled Iron-sorbitol. - The physical and chemical properties of stable iron-sorbitol are described elsewhere (Lindvall and Andersson, 1961; Svard, 1961; Svard and Lindvall, 1961 the toxicity of larger doses of the preparation when given in this way is not known. In neither patient was there any subjective or objective reaction. In all cases aliquots were retained for determining the activity of the injected dose. Surface Counting.-Changes in activity over injection site, control site (opposite arm or buttock), heart, liver, spleen, and marrow (sacrum) were recorded at selected time intervals from T + 2 minutes to T+10 days. The apparatus and technique used have been previously described (Wetherley-Mein, Hutt, Langmead, and Hill, 1956) . The observed activities of each organ were corrected for decay and counter variation and finally expressed as a percentage of the activity of that organ at T + 2 minutes.
Plasma and Red-cell Activity.-Blood samples were obtained at each surface-count determination throughout the period T+2 minutes to T+10 days. For each sampling time 5 ml. of plasma and 5 ml. of haemolysed whole blood were counted separately in a well-type scintillation counter. Blood volume was determined by a 5'Cr dilution technique (Mollison, 1960) . Total plasma and red-cell activities at each sampling-time were then calculated and expressed as the percentage of the injected dose circulating at that time.
Urinary Excretion.-All urinary samples were collected during the period T + 0 to T + 48 hours. Time of voiding and volume of each sample were recorded and 5-ml. aliquots were counted in the well-type scintillation counter. The percentage of the injected dose excreted in each sample was determined. In two patients (Cases S and 9) urinary collection was incomplete.
Plasma Iron.-This was determined by the method of Bothwell and Mallett (1955) .
Other Haematological Data.-These were obtained by standard techniques (Dacie, 1956 (range 6-9%) in the normal controls.
Urinary Excretion.-In all patients there was a considerable urinary excretion of labelled iron in the 24-hour period after injection, and this appeared to be maximal in the first 12 hours (Fig. 3) . The most rapid loss occurred in the one patient receiving the dose intravenously in whom complete urinary collection was obtained (Figs. 3 and 4) . The percentages of the injected doses excreted during the whole 48-hour period of urinary collection are shown in the Table. Body Distribution After Injection
The mean 59Fe surface patterns and the mean plasma and red-cell 59Fe activity in the iron-deficient patients, greater deviation of iron to the marrow in the irondeficient patients and to the liver in the controls. Plasma and Red-cell Activity.-Measurement of activity in plasma and whole-blood samples showed little overlap of plasma and red-cell activity. Wholeblood activity in the first 24 hours after injection was due essentially to isotope carried in the plasma and subsequently to isotope in red cells. The curves representing plasma activity in the intravenous group (Fig. 5) 
Discussion
Although the metabolism of injected 59Fe sorbitol in general resembles that of 59Fe dextran and 59Fe citrate there are certain important differences which are probably determined by the low molecular weight and the initial stability of the iron-sorbitol-citricacid complex in the plasma.
After intramuscular injection the rates of removal of the 59Fe-sorbitol complex and 59Fe dextran are strikingly different. Grimes and Hutt (1957) found Ti buttock clearance times ranging from 10 to 40 hours as compared with the mean T-deltoid clearance times for 59Fe sorbitol of 46 minutes (iron-deficient group) and 174 minutes (controls) observed in this study. Grimes and Hutt, unlike ourselves, found no difference in clearance rates between iron-deficient and control patients, but the numbers of patients in each group in their series and ours are probably too small for this difference to be significant. Clearance of the 59Fe sorbitol from the injection site is almost complete by 10 days (Table, Figs. 1 and 2), whereas Grimes and Hutt found that 17-40% of the 59Fe dextran remained at the site after 450-1,224 hours. Use and movement of the muscle injected certainly affects absorption from it, and in our patients, at bed rest, the injection of a relatively small volume (1.5 ml.) into the deltoid might be expected to produce more rapid absorption than the larger volumes (5 ml.) given in the buttock in the 59Fe dextran study.
However, the findings in one patient (Case 1) who received a buttock injection suggested that the use of the deltoid site did not obviously modify the clearance rates, and it seems most probable that the differences in clearance of 59Fe sorbitol and 59Fe dextran are a function of the different molecular weights of the two substances.
This view is supported by the results of studies on mechanisms of absorption from muscle in animals. Barnes and Trueta (1941) showed that toxins and snake venoms with molecular weights of 5,000-20,000 were directly absorbed by the blood-stream while with molecular weights greater than 20,000 absorption was by lymphatics. The molecular weights of the ironsorbitol complex are of the order of 5,000 (Eriksson, 1961) , and it has been established that this substance is primarily absorbed by the capillaries (Svaird and Lindvall, 1961) , while the 59Fe dextran, with a molecular weight certainly greater than 20,000, is absorbed primarily by lymphatics (Beresford, Golberg, and Smith, 1957) .
Although after its absorption into the blood-stream it seems that some fraction of the iron of the 59Fe sorbitol complex becomes bound to transferrin (Svard and , the greater part of it, like 59Fe dextran, is stable and is cleared from the plasma unchanged. In this respect both these substances differ from the iron of "Fe citrate, virtually all, of which is immediately bound to transferrin if this is available (Loeffler, Rappoport, and Coffins, 1955) .
Both the dextran and the citrate iron thus come to exist in the plasma in high-molecular-weight complexes and, as such, are completely available for clearance from the plasma to marrow and reticulo-endothelial storage sites such as the liver. In contrast, although varying proportions of the 59Fe-sorbitol complex are also cleared to marrow and liver, its existence in the plasma predominantly as a substance of low molecular weight permits its excretion in the urine. The relationship between plasma activity and urinary loss (Fig. 4) , particularly in the patient receiving it intravenously (Case 6), suggests that the rate of urinary excretion is a direct function of the plasma level. This is obviously of some importance in terms of optimal route and therapeutic dose, since animal studies suggest that increasing doses are associated with increased plasma levels (Lindvall and Andersson, 1961) and presumably, therefore, with increased urinary loss.
The findings in the present study demonstrate that, like 59Fe dextran and 59Fe citrate, the 59Fe sorbitol not excreted in the urine moves from plasma to marrow and probably to liver as well, its partition between marrow and liver being possibly a function of the degree of iron deficiency. The utilization curves of all these preparations are similar and, in all, labelled iron appears in erythrocytes about 24 hours after injection. The 10-day utilization of tracer doses of 59Fe citrate is between 70% and 85% in control patients and 100% in iron-deficient patients. In the previous iron-dextran and the present iron-sorbitol studies, where therapeutic rather than tracer doses were used, the 10-day utilization of the available fractions of the injected dose was, not surprisingly, almost invariably lower than this (see Table) . The findings in the present study and in animal studies suggest that the fractions of iron-sorbitol unaccounted for by T+ 10 days are stored in the liver and possibly diffuse into tissue fluids (Lindvall and Andersson, 1961; S. Wahlqvist, 1962, personal communication) .
Longer-term studies in untreated patients will be necessary to determine whether this stored fraction is readily available for haemoglobin synthesis, but comparison of the utilization curves of the iron-deficient and control patients (Figs. 1 and 2) suggests that in the iron-deficient group maximal utilization has not occurred by T+ 10 days and that there is further utilization of the stored fraction.
Sumnmay
Studies with 59Fe-labelled iron-sorbitol complex in man showed that after intramuscular injection there was rapid clearance from the site of injection.
The mean T{ deltoid clearance for 59Fe sorbitol vas 46 minutes in the iron-deficient group and 174 minutes in the controls. Clearance from the injection site was almost complete by ten days. These 59Fe sorbitol clearance times from the injection site are strikingly shorter than those for iron dextran.
It seems probable that the differences in clearance of 59Fe sorbitol and 59Fe dextran are a function of the different molecular weights of the two substances.
The low molecular weight of iron-sorbitol complex resulted in a rapid excretion in the urine. This was maximal in the,first twelve hours. The urinary excretion for the 48-hour period after injection ranged from 18% to 53%.
The red-cell utilization at ten days ranged from 27% to 66 %. Utilization in the iron-deficient group was greater than in the control group. The utilization curve in the iron-deficient group showed that maximal utilization had not occurred by T+ 10 days.
The surface counting data suggested that the retained fraction of iron not utilized for haemoglobin synthesis by T+ 10 days (16% to 40%) was stored predominantly in the liver.
We are grateful to Dr. S. Wahlqvist, of Astra, Sweden, for providing the "9Fe sorbitol. The expenses of the investigation were partly borne by the Endowment Fund, St. Thomas's Hospital.
In order to administer iron parenterally without incurring the toxic effects of the ionized metal, ferric hydroxide has been bound to carbohydrates to form complexes of fairly high molecular weight. These complexes simulate the binding of iron by the betaglobulin transferrin, the physiological carrier of iron in the circulation. The first clinically useful carbohydrate complex was made with saccharose, later with dextrans and dextrins, and more recently with sorbitol. In 1959 Richmond reported that iron-dextran (" imferon ") induced sarcomas in rats after intramuscular injection in massive doses. Haddow and Horning (1960) confirmed this in both rats and mice. This unexpected observation restimulated interest in the role which metals may play in carcinogenesis; it also demanded reconsideration of the use of iron-carbohydrate complexes in man for the parenteral treatment of iron deficiency.
The discussion has centred mainly on the massive dose of iron complex used to induce sarcomas in experimental animals. Golberg and his co-workers emphasized the systemic effects of massive iron overload, which include reticulo-endothelial stimulation, altered tissue enzyme activity, increased tissue peroxide and lipofuscin polymer formation, indicative of defective vitamin-E metabolism. They propose that the iron dosage given to experimental animals should be compared to the dosage used in treatment on a body-weight basis in order to assess the possible tumour risk in man. They point out that similar biochemical changes occur at the site of injection, and postulate that the bulk of tissue available for injection relative to the amount injected is also relevant (Golberg et al., 1960; Baker et al., 1961) . Haddow and Horning (1960) concluded that sarcoma induction by iron-dextran is essentially a local action. This implies that the absolute amount of iron injected is the determinate factor rather than the body-weight/ dose ratio (Haddow, 1960) .
Most experimental work so far has been with mice and rats, which are evidently highly susceptible species. Haddow and Horning record a single induced tumour in a hamster; they failed to produce tumours in guineapigs, but of three surviving rabbits in a group of six treated with massive iron-dextran one has produced a tumour after a latent period of 39 months (Haddow, 1961) . Golberg and his co-workers (1960) failed to induce tumours in dogs.
Previously published experimental findings in rats are summarized in Table I . Total dosages of 250 mg. or more of iron as iron-dextran given intramuscularly or subcutaneously in divided doses into a single site produce high yields of sarcomas varying from 55% to 92% of animals at risk. At such dose levels the sarcogenic action of iron-dextran is evidently easily reproducible in different laboratories with different strains of animal. The results of Golberg and his co-workers (1960) are of particular interest, since their experiments differed in design from others: the doses were given alternately into two limbs instead of into a single site. Injecting 116 mg. of iron as iron-dextran into each limb -that is, a total of 232 mg. Fe-they obtained only a 5% yield of tumours, compared with the much higher yields obtained when a similar total dose is given into a single site. There is perhaps evidence here which favours the " local action " hypothesis rather than the systemic effect of iron overload as the significant factor in iron sarcogenesis. Table I also shows a comparison made by Lundin (1962) of three iron complexes. He found that both iron-dextrin arid iron-dextran in high dosage produced high yields of tumours in rats, whereas ironsorbitol produced a single tumour, which he described as a fibroma rather than a sarcoma. The significance of these results is discussed below. The object of the experiment described here was to test the effect in mice of subcutaneous injection of a
